Houston Lake`s objective is to become a gold producer by surfacemining its West Cedartree gold project and developing its 100% owned andoptioned properties. The Company has a total of 34,257,638 common shares issuedand outstanding. For additional information, please visit us at. Forward-looking StatementsThe TSX Venture Exchange has not reviewed and does not accept responsibility forthe adequacy or accuracy of this release. This release includes certainstatements that may be deemed "forward-looking statements". All statements inthis release, other than statements of historical facts, that address futureproduction, reserve potential, exploration drilling, exploitation activities andevents or developments that the Company expects are forward-looking statements.Although the Company believes the expectations expressed in such forward-lookingstatements are based on reasonable assumptions, such statements are notguarantees of future performance and actual results or developments may differmaterially from those in the forward-looking statements.

Factors that couldcause actual results to differ materially from those in forward lookingstatements include market prices, exploitation and exploration successes,continued availability of capital and financing, and general economic, market orbusiness conditions. Investors are cautioned that any such statements are notguarantees of future performance and those actual results or developments maydiffer materially from those projected in the forward-looking statements. Formore information on the Company, Investors should review the Company`sregistered filings what are available at Lake MiningE. Grayme Anthony P.Geo., MBA, 705-897-7622President and CEOFax: rIn Canada:Linx Partners Ltd.Wanda Cutler, 416-603-4646orIn United States:ICSGeorge Duggan, 818-542-6880 Copyright Business Wire 2009. SANTA CLARA, Calif.--(Business Wire)--OptiMedica Corp., a global ophthalmic company, has announced that its PASCALPhotocoagulator technology will be discussed as part of 17 presentations at TheAssociation for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting,Fort Lauderdale, Fla. Authored by a group of highly distinguishedophthalmologists from around the world, the presentations cover a range ofresearch topics including: clinical experience with PASCAL; the comparisonbetween PASCAL and conventional photocoagulators; the combination of PASCAL andpharmacology; and new and potential clinical applications of PASCAL.

Conclusions from a number of the presentations support PASCAL`s potential tosignificantly increase the precision, safety and efficiency of thephotocoagulation procedure, which may lead to improved patient outcomes. Presentation Highlights: PASCAL Versus Conventional PhotocoagulatorsPanretinal photocoagulation (PRP) has traditionally been performed over multiplesessions using conventional single-spot lasers. However, recent research hasshown that multiple session PRP may prolong the duration of macula edema(retinal thickening that can lead to blindness) after the procedure.* Two ARVOpresentations from Japan and the United Kingdom offer evidence suggesting thatsingle-session PRP with PASCAL is preferable to both single-session andmultiple-session treatment using conventional single-spot laser. In "PASCAL Laser Photocoagulation Induces Less VEGF (Vascular Endothelial GrowthFactor) Expression in Murine Retina Than Conventional Laser Treatment," YoshioHirano, M.D. (Nagoya University Medical Sciences, Japan) will present findingsof a mouse study that concluded PASCAL induced significantly less vascularendothelial growth factor (VEGF) in the sensory retina and may induce lessmacular edema after PRP, suggesting PASCAL may be safer than conventional laser.In addition, Paulo E Stanga, M.D. (Manchester Royal Eye Hospital, ManchesterBiomedical Research Center, University of Manchester, United Kingdom) willpresent "Manchester Study of Pattern Scanning Laser (PASCAL) PanretinalPhotocoagulation (PRP) in Proliferative Diabetic Retinopathy [MAPASS]: 1500Burns Pattern vs. Single-Spot Multiple Sessions PRP." This randomized studycompared single-session PRP treatment with PASCAL against conventional lasertreatment spread over three sessions.

Findings showed that single-sessiontreatment with PASCAL was not only ten times faster than the conventionaltreatment, but it also induced no macula edema at one month and three months.Therefore, the authors concluded that single-session treatment with PASCAL isboth more efficient and safer than multi-session treatment with conventionallaser. Another comparative study looks at structural changes to the retina followingPRP with PASCAL and conventional laser Presented by Franz Prager, M.D. (MedicalUniversity of Vienna), "Comparison of Retinal Morphologic Changes UsingConventional and PASCAL Laser System" used advanced imaging technology (opticalcoherence tomography, or OCT) to compare PASCAL burns with those produced withconventional laser. The authors concluded that PASCAL burns are more uniform insize and shape, with spots that are round and equal in both size and spacing.This suggests that PASCAL delivers a significantly higher level of precision andconsistency than conventional lasers. "The volume and caliber of PASCAL-focused presentations at this year`s ARVOmeeting are a remarkable testament to the widespread physician interest in ourtechnology," said Mark J. Forchette, president and chief executive officer ofOptiMedica. "Our rapidly expanding body of scientific evidence strongly supportsPASCAL`s ability to improve the precision, efficiency and safety of thephotocoagulation procedure - key benefits that can help physicians providebetter treatment and a better experience for patients.

We appreciate all thephysicians that developed these studies and presentations, and feel confidentthat their work will represent a significant contribution to this year`s ARVOmeeting." About ARVOThe Association for Research in Vision and Ophthalmology (ARVO) is the largesteye and vision research organization in the world. Members include more than12,000 researchers from over 70 countries. The Association encourages andassists research, training, publication and dissemination of knowledge in visionand ophthalmology. Our annual meeting (May 3-7 in Fort Lauderdale, Fla.) bringstogether more than 10,000 scientists and practitioners to explore and share thelatest research in eye disease and treatment For more information, visit.